New Drugs and Clinical Research · us
Once-weekly antifungal seeks transplant prevention indication: rezafungin granted FDA priority review
The application for Rezzayo seeks to expand its use from treating infections to preventing fungal disease after allogeneic hematopoietic stem cell transplantation, with an FDA decision targeted for the first quarter of 2027. A Phase 3 trial supports the application, but approval of the new indication remains subject to a full benefit-risk review.
For adults undergoing allogeneic hematopoietic stem cell transplantation, preventing invasive fungal disease is an important part of transplant care. The once-weekly antifungal rezafungin is now seeking a role in this preventive setting. CorMedix Therapeutics announced on October 19 that the U.S. Food and Drug Administration (FDA) had accepted the supplemental New Drug Application for its Rezzayo and granted it priority review.
The application was submitted by Mundipharma, CorMedix’s global development partner, with an FDA review decision targeted for the first quarter of 2027. This development provides a clearer regulatory timeline for the new use, but neither acceptance of the application nor priority review constitutes approval. Rezzayo remains unapproved for the prevention of invasive fungal disease.
The application is primarily supported by the pivotal Phase 3 ReSPECT trial. The study enrolled adults undergoing allogeneic hematopoietic stem cell transplantation and compared the efficacy and safety of once-weekly rezafungin with a standard antimicrobial regimen for preventing invasive fungal disease. CorMedix said positive topline results were announced in April of this year; RTTNews’s coverage of the same event also noted that these results supported the application.
However, the announcement did not provide participant numbers, infection rates, differences between groups, or detailed safety data. It therefore does not yet allow an assessment of the magnitude of the preventive effect, and “positive results” cannot be directly interpreted as superiority to the standard regimen. Once-weekly dosing is a feature of this study; whether it can translate into practical advantages in care still requires support from specific clinical data.
Rezzayo is an echinocandin antifungal. According to the announcement, its current U.S. indication is for the treatment of candidemia and invasive candidiasis in adults and pediatric patients aged 12 years and older who have limited or no alternative treatment options. This application concerns preventive use in adult transplant patients; the existing treatment approval does not directly establish the safety and efficacy of this new use.
If the prevention indication is approved, CorMedix plans to begin related promotional activities in the second half of 2027. However, the FDA could still request additional information, extend the review, or approve an indication narrower than the one sought. The key questions ahead are how the full ReSPECT data support preventive use and which patients the final approved indication may cover.